GCRF_NF55 Fast-track vaccine cold-chain assessment and design for mass scale COVID-19 vaccination in Bangladesh (VaCoBD)

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: EP/V028332/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $620,898.96
  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Birmingham
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Universal vaccine access is an existing major challenge in low-income countries, mainly due to the lack of robust cold-chains, resulting in loss of potency for +25% of vaccines. Mass vaccination for COVID-19 globally will require a new fast-track approach to assess, re-engineer and build upon available cold-chain logistics assets and systems, to deliver the vaccines at scale and speed never before considered. We aim to evaluate the capacity and preparedness of the cold-chain framework of Bangladesh as a case study country for mass scale COVID-19 vaccination, and assist the policymakers in defining optimised, sustainable interventions and lasting legacy opportunities. Our objectives are: (1) evaluating the context and resilience of cold-chains and resources in Bangladesh, collecting primary data for a robust assessment of the cold chain capacity and gaps; (2) developing a bottom-up whole systems approach building upon existing logistics infrastructure, and distribution systems for mass scale COVID-19 vaccination including modal shifts; (3) developing a cost-benefit analysis framework for the bottom-up (vaccine) systems model; (4) assessing different intervention scenarios for mass-scale COVID-19 vaccination preparedness, and helping shape the country's immunisation strategies and priorities; (5) informing policymakers and other key stakeholders, including Monetary Financial Institutions about the cost-effective intervention alternatives for cold-chain development for mass-scale vaccination for COVID-19, which may be useful for future emergency or disasters; and (6) disseminating learnings to other countries, including methodology, to assess their requirements and to simulate best options for creating sustainable temperature-controlled supply-chains for health and medical supplies in epidemics and natural disasters.